Is WT1 a promising candidate peptide for TCR-based immunotherapies?
Is WT1 a promising candidate peptide for TCR-based immunotherapies?
|
Loading...
Lütfen bekleyiniz...
Type
Size

İlgili Videolar

Is WT1 a promising candidate peptide for TCR-based immunotherapies?

Is WT1 a promising candidate peptide for TCR-based immunotherapies?

|
T-cell bispecific antibody targeting intracellular WT1 in AML

T-cell bispecific antibody targeting intracellular WT1 in AML

|
AML: Targeting Wilms' tumor 1 with WT1-TCB

AML: Targeting Wilms' tumor 1 with WT1-TCB

|
Challenges with immunotherapy in AML: target antigen selection, T-cell exhaustion and more

Challenges with immunotherapy in AML: target antigen selection, T-cell exhaustion and more

|
Selecting TCRs: understanding peptide-HLA-TCR interactions

Selecting TCRs: understanding peptide-HLA-TCR interactions

|
Galinpepimut-S: mechanism of action and use in AML, ovarian cancer & mesothelioma

Galinpepimut-S: mechanism of action and use in AML, ovarian cancer & mesothelioma

|
CD1c-restricted T cells as a potential immunotherapy for leukemia

CD1c-restricted T cells as a potential immunotherapy for leukemia

|
TCR gene editing in cancer therapy

TCR gene editing in cancer therapy

|
Immatics’ Clinical ACTengine® TCR-T Trials: A Patient’s Journey

Immatics’ Clinical ACTengine® TCR-T Trials: A Patient’s Journey

|
Targeted treatment of AML using T cell recruiting antibody constructs

Targeted treatment of AML using T cell recruiting antibody constructs

|
TCR-based cell therapies for hematological malignancies

TCR-based cell therapies for hematological malignancies

|
Identifying novel antigens for TCR T-cell therapy

Identifying novel antigens for TCR T-cell therapy

|
Boosting Immune Defenses Against Cancer, with Philip D. Greenberg

Boosting Immune Defenses Against Cancer, with Philip D. Greenberg

|
Zelluna Immunotherapy

Zelluna Immunotherapy

|
Antibody-based therapy in AML: immunotoxins and BiTEs

Antibody-based therapy in AML: immunotoxins and BiTEs

|
Measuring T-cell receptor sequences and their antigens - Drew Pardoll and Alex Baras

Measuring T-cell receptor sequences and their antigens - Drew Pardoll and Alex Baras

|
The promise of CD123-directed immunotherapy in AML and agents of interest

The promise of CD123-directed immunotherapy in AML and agents of interest

|
Peptomyc: Drugging the undruggable: treating cancer with anti-Myc peptides

Peptomyc: Drugging the undruggable: treating cancer with anti-Myc peptides

|
Defined Tumor Antigen Specific T Cells Potentiate Personalized TCR T Cell Therapy

Defined Tumor Antigen Specific T Cells Potentiate Personalized TCR T Cell Therapy

|
Immunotherapy With Erythrocytes Used as Tumor Antigen Delivery System

Immunotherapy With Erythrocytes Used as Tumor Antigen Delivery System

|
Copyright. All rights reserved © 2025
Rosebank, Johannesburg, South Africa